Jingfen Wang
Impact in
- Molecular Medicine top 10%
- Antibiotic Resistance in Bacteria
-
- Ovarian function and disorders
Papers in
- Oncology 17
- HER2/EGFR in Cancer Research 13
- Cancer Treatment and Pharmacology 7
- Lung Cancer Research Studies 2
-
- Advanced Breast Cancer Therapies 13
- Co-authors
- Shenghai Chang (1 shared paper)Liangliang Shen (1 shared paper)Wenda Wang (1 shared paper)Xing Zhang (2 shared papers)Zihui Huang (1 shared paper)Jian Xu (1 shared paper)Jian‐Ren Shen (1 shared paper)Tingyun Kuang (1 shared paper)
- Journals
- Journal of Clinical Oncology (11 papers)Cancer Research (3 papers)Emerging Microbes & Infections (2 papers)Clinical Cancer Research (1 paper)Targeted Oncology (1 paper)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Jingfen Wang
27 papers receiving 356 citations
Peers
Comparison fields: 5 of 69
- Molecular Medicine 40
- Reproductive Medicine 40
- Microbiology 22
- Endocrinology 17
- Molecular Biology 185
Countries citing papers authored by Jingfen Wang
This map shows the geographic impact of Jingfen Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingfen Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingfen Wang more than expected).
Fields of papers citing papers by Jingfen Wang
This network shows the impact of papers produced by Jingfen Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingfen Wang. The network helps show where Jingfen Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Jingfen Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 96 | |
| 2 | 2013 | 54 | |
| 3 | 2013 | 44 | |
| 4 | 2021 | 37 | |
| 5 | 2022 | 29 | |
| 6 | 2019 | 20 | |
| 7 | 2022 | 14 | |
| 8 | 2021 | 11 | |
| 9 | 2010 | 9 | |
| 10 | 2023 | 8 | |
| 11 | 2022 | 7 | |
| 12 | 2020 | 6 | |
| 13 | 2021 | 4 | |
| 14 | 2023 | 4 | |
| 15 | 2023 | 4 | |
| 16 | 2024 | 2 | |
| 17 | 2025 | 1 | |
| 18 | 2023 | 1 | |
| 19 | 2005 | 1 | |
| 20 | 2025 | 1 |
About Jingfen Wang
Jingfen Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 30 papers that have together received 360 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (13 papers), Advanced Breast Cancer Therapies (13 papers), Cancer Treatment and Pharmacology (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Protein Degradation and Inhibitors (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Lung Cancer Research Studies (2 papers). The work is most often cited by research in Molecular Medicine (40 citations), Reproductive Medicine (40 citations), Microbiology (22 citations), Endocrinology (17 citations) and Molecular Biology (185 citations). Jingfen Wang has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Shenghai Chang, Liangliang Shen, Wenda Wang, Xing Zhang, Zihui Huang, Jian Xu, Jian‐Ren Shen, Tingyun Kuang, Guangye Han and Yangyang Du. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Emerging Microbes & Infections, Clinical Cancer Research and Targeted Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.